Abstract
Pharmacokinetic and pharmacodynamic properties of tolfenamic acid (TA) in calves were determined in serum and fluids of inflamed (carrageenan administered) and non‐inflamed subcutaneously implanted tissue cages after intramuscular administration both alone and in combination with marbofloxacin (MB). MB significantly altered the pharmacokinetics of TA: mean values wereCmax = 2.14 and 1.64 μg/mL,AUC = 27.38 and 16.80 μg·h/mL, Vd(area)/F = 0.87 and 1.17 L/kg, and ClB/F = 0.074 and 0.128 L/kg/h, respectively, after administration of TA alone and TA + MB.T1/2K10and MRT were not significantly different for the two treatments. The pharmacodynamic properties of TA were not influenced by MB co‐administration, in spite of the alterations in some TA pharmacokinetic parameters. TA inhibited prostaglandin E2(PGE2) synthesisin vivoin inflammatory exudate by 50–88% for up to 48 h after both TA treatments. Inhibition of synthesis of serum thromboxane B2(TxB2)ex vivoranged from 40 to 85% up to 24 h after both TA and TA + MB. From the derived pharmacokinetic and eicosanoid inhibition data for TA, pharmacodynamic parameters for serum TxB2and exudate PGE2inhibition expressing efficacy (Emax = 78.1 and 97.5%), potency (IC50 = 0.256 and 0.265 μg/mL), sensitivity (N = 1.96 and 2.29) and the pharmacokinetic parameter equilibration time (t1/2Ke0 = 0.695 and 24.0 h), respectively, were determined. In this model TA was a nonselective inhibitor of cyclo‐oxygenase (COX) (COX‐1:COX‐2 IC50ratio = 1.37). TA, both alone and co‐administered with MB, did not affect leucocyte numbers in exudate, transudate or blood. Partial attenuation of skin temperature rise over inflamed tissue cages and reduction of zymosan‐induced skin swelling were recorded after administration of TA and TA + MB with no significant differences between the two treatments. These data provide a basis for the rational use of TA in combination with MB in calf medicine.

This publication has 47 references indexed in Scilit: